Compare BIOX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIOX | ATOS |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.2M | 100.8M |
| IPO Year | N/A | 2012 |
| Metric | BIOX | ATOS |
|---|---|---|
| Price | $1.64 | $0.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.42 | ★ $6.33 |
| AVG Volume (30 Days) | 370.1K | ★ 911.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,158,904.00 | N/A |
| Revenue This Year | $1.25 | N/A |
| Revenue Next Year | $27.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.20 | $0.55 |
| 52 Week High | $7.44 | $1.29 |
| Indicator | BIOX | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 40.51 |
| Support Level | $1.40 | $0.68 |
| Resistance Level | $1.65 | $0.99 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 48.17 | 11.57 |
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.